Lv31
288 积分 2024-03-15 加入
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
10分钟前
待确认
PARP Inhibitors for Breast Cancer Treatment:A Review
1个月前
已完结
Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer
1个月前
已完结
The Evolving Landscape of HER2 Targeting in Breast Cancer
1个月前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
2个月前
已完结
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
2个月前
已完结
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial
2个月前
已完结
Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer
2个月前
已完结
Response assessment criteria for brain metastases: proposal from the RANO group
4个月前
已完结
Response assessment criteria for brain metastases: proposal from the RANO group
4个月前
已完结
皖公网安备34019202002308
